Information Provided By: 
Fly News Breaks for August 9, 2016
EPZM
Aug 9, 2016 | 08:09 EDT
Leerink analyst Seamus Fernandez says Epizyme announced during its Q2 earnings call that it now plans to report results from its two ongoing Phase 2 trials of tazemetostat in the first half of 2017, rather than at medical conferences in late 2016 as previously anticipated. The analyst believes the delay may allow for data to mature and says the weakness in the stock is unwarranted. Fernandez reiterates an Outperform rating and $39 price target on the shares.
News For EPZM From the Last 2 Days
There are no results for your query EPZM
